The abovementioned cell-based studies demonstrated that glecirasib had a remarkable selectivity (>500-fold in both p-ERK and cell viability assays) to specifically inhibit KRAS signaling and the growth of KRAS p.G12C–mutant cancer cells over non-KRAS G12C cells. This evidence concerns the gene KRAS and cancer.